List of Excipients in Branded Drug MYOVIEW

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Medi-Physics Inc dba GE Healthcare	MYOVIEW	tetrofosmin	17156-024	DISODIUM SULFOSALICYLATE	2030-03-10
Medi-Physics Inc dba GE Healthcare	MYOVIEW	tetrofosmin	17156-024	SODIUM BICARBONATE	2030-03-10
Medi-Physics Inc dba GE Healthcare	MYOVIEW	tetrofosmin	17156-024	STANNOUS CHLORIDE	2030-03-10
Medi-Physics Inc dba GE Healthcare	MYOVIEW	tetrofosmin	17156-026	ASCORBIC ACID	2030-03-10
Medi-Physics Inc dba GE Healthcare	MYOVIEW	tetrofosmin	17156-026	SODIUM BICARBONATE	2030-03-10
Medi-Physics Inc dba GE Healthcare	MYOVIEW	tetrofosmin	17156-026	STANNOUS CHLORIDE	2030-03-10

Myoview Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Myoview is a technetium Tc 99m-labeled myocardial perfusion imaging kit containing tetrofosmin. Its commercial value is driven less by conventional formulation differentiation than by radiochemical performance, kit stability, sterile manufacturing, supply reliability, and hospital workflow. The strongest opportunities are improved lyophilized-kit robustness, automated compounding compatibility, regional supply, and differentiated service models for nuclear cardiology providers.

What is Myoview and how is it formulated?

Myoview is a diagnostic radiopharmaceutical kit for the preparation of technetium Tc 99m tetrofosmin injection. The nonradioactive vial contains tetrofosmin and formulation components that support complexation with technetium, maintain chemical stability, and permit reconstitution with sodium pertechnetate Tc 99m solution. The commercial product is associated with GE HealthCare and is approved in the United States under NDA 020923.[1,2]

The product is supplied as a sterile, nonpyrogenic lyophilized preparation. The radioactive component is not present in the unopened vial. A nuclear pharmacy or hospital radiopharmacy adds sodium pertechnetate Tc 99m before administration.

Product attribute	Myoview profile
Active imaging agent	Technetium Tc 99m tetrofosmin after reconstitution
Nonradioactive precursor	Tetrofosmin
Dosage form	Sterile lyophilized kit for injection
Administration	Intravenous
Primary use	Myocardial perfusion imaging
Manufacturing model	Kit production plus site-specific radiolabeling
Principal customers	Hospitals, nuclear pharmacies, imaging centers
Main competitors	Cardiolite, generic technetium Tc 99m sestamibi, other myocardial perfusion agents
Regulatory pathway	FDA-approved diagnostic radiopharmaceutical NDA
Principal formulation risks	Radiochemical purity, technetium incorporation, sterility, endotoxin control, reconstitution consistency

The excipient system is functional rather than patient-facing. It is selected to preserve the ligand and support formation of the technetium complex during the short operating window between reconstitution and administration.

What excipients are used in Myoview?

Public product information identifies tetrofosmin as the active nonradioactive ingredient and lists formulation components including stannous chloride dihydrate, sodium chloride, and a sulfosalicylate salt used in the lyophilized kit system.[1,2] The exact presentation and labeling terminology should be controlled against the current approved package insert for each market because excipient descriptions and quantities can differ by jurisdiction.

Formulation component	Technical function
Tetrofosmin	Technetium-binding ligand that forms the myocardial perfusion imaging complex
Stannous chloride dihydrate	Reducing agent that converts pertechnetate into a chemical state suitable for ligand complexation
Sodium chloride	Ionic-strength and tonicity support
Sulfosalicylate component	Matrix, buffering, or stabilization support in the lyophilized formulation
Sodium pertechnetate Tc 99m	Added at the point of use; radioactive technetium source rather than a stored kit excipient

The stannous component is central to product performance. Excess oxidation, low reducing capacity, or poor moisture control can reduce labeling efficiency and increase free technetium or hydrolyzed technetium species. Those impurities can alter biodistribution and increase background activity.

What is the role of lyophilization?

Lyophilization is the principal formulation-enabling technology. It protects the ligand and reducing agent during storage and creates a rapidly reconstitutable solid with controlled moisture exposure.

A commercial development program should evaluate:

• Residual moisture and its impact on stannous-ion activity.
• Cake structure and reconstitution time.
• Oxygen exposure during filling and stoppering.
• Container-closure integrity.
• Stability under excursions outside the labeled storage range.
• Radiochemical purity after reconstitution at the beginning and end of shelf life.
• Compatibility with hospital or nuclear-pharmacy reconstitution equipment.

A reformulated product that uses a different buffer or bulking system would need to demonstrate equivalent radiochemical purity, sterility, endotoxin performance, biodistribution, and clinical utility. Small changes in the excipient system can affect technetium reduction kinetics and therefore cannot be treated as ordinary generic formulation substitutions.

How does Myoview compare with Cardiolite and generic sestamibi?

Myoview competes mainly with technetium Tc 99m sestamibi products, including Cardiolite and generic equivalents. The molecules differ, but both are technetium-based myocardial perfusion agents used in similar nuclear cardiology workflows.

Attribute	Myoview	Cardiolite and generic sestamibi
Ligand	Tetrofosmin	Sestamibi
Kit format	Lyophilized radiolabeling kit	Lyophilized radiolabeling kit
Radioactive isotope	Tc 99m	Tc 99m
Primary indication	Myocardial perfusion imaging	Myocardial perfusion imaging
Excipient strategy	Optimizes tetrofosmin complexation and kit stability	Optimizes sestamibi complexation and kit stability
Substitution	Clinical and operational decision, not simple excipient substitution	Same limitation
Procurement drivers	Price, availability, labeling reliability, workflow	Price, availability, labeling reliability, workflow

Clinical guidelines recognize both technetium-based agents as established options for myocardial perfusion imaging.[3] A new entrant therefore needs a practical advantage. Lower acquisition cost alone may be insufficient if the product has shorter dating, more difficult reconstitution, lower radiochemical purity, or inconsistent availability.

What commercial opportunities exist for Myoview excipient innovation?

The most attractive opportunities are incremental. They target product reliability and workflow rather than a new therapeutic claim.

Higher-stability lyophilized kits

A formulation with improved resistance to moisture and oxygen could extend shelf life, reduce vial failures, and improve distribution into markets with weak cold-chain infrastructure. Potential approaches include:

• Optimized residual-moisture control.
• Improved stopper and vial-closure systems.
• Oxygen-reduced filling conditions.
• Alternative stabilizing salts.
• More robust lyophilization cycles.
• Packaging with enhanced barrier properties.

Any change must preserve the ligand-to-technetium reaction profile and the product's validated radiochemical-purity specifications.

Faster and more forgiving reconstitution

Nuclear pharmacies process many doses under time pressure. A kit that dissolves rapidly with less agitation could reduce preparation errors. Commercial differentiation could include:

• Shorter reconstitution time.
• Reduced dependence on exact mixing technique.
• Lower particulate formation.
• Compatibility with automated dose-dispensing systems.
• Clearer visual confirmation of complete dissolution.

A faster kit has economic value because it can reduce labor time and improve throughput without changing the clinical indication.

Improved automated-compounding compatibility

Automation is a significant formulation opportunity. The product should be assessed for compatibility with:

• Automated radiopharmaceutical compounders.
• Shielded syringe-filling systems.
• Standard Tc 99m eluate volumes.
• Different generator eluate concentrations.
• Closed-system transfer devices.
• Hospital nuclear pharmacy batch workflows.

A kit that performs reliably across automated platforms can gain access to larger institutional accounts even when its unit price is similar to established products.

Extended dating and global distribution

The kit is nonradioactive before reconstitution, allowing centralized manufacturing and distribution. Longer dating could reduce inventory losses and improve supply continuity. The commercial opportunity is strongest in countries where nuclear pharmacies order infrequently or where transportation delays are common.

The development target should not be shelf life alone. It should be shelf life combined with:

• Radiochemical purity at release and expiry.
• Sterility assurance.
• Endotoxin limits.
• Reconstitution time.
• Container-closure integrity.
• Stability after transport vibration and temperature excursions.

What FDA regulatory issues apply to a Myoview reformulation?

A reformulated Myoview-type kit would generally require a regulatory pathway tied to the extent of change and the sponsor's rights to the reference product. A new applicant could pursue an NDA strategy, while an authorized product owner could assess a supplemental application for certain changes. A generic radiopharmaceutical pathway may be available only if the product can meet the applicable requirements for pharmaceutical equivalence, bioequivalence or other product-specific standards, and labeling.

Key FDA review issues would include:

1. Chemistry, manufacturing, and controls. The sponsor must define raw-material controls, lyophilization parameters, vial filling, closure integrity, and release testing.

2. Radiochemical purity. The sponsor must characterize labeling efficiency and impurities across the proposed shelf life and relevant technetium concentrations.

3. Sterility and endotoxin control. The kit is intended for intravenous administration after radiolabeling, making sterile manufacturing and aseptic processing central regulatory issues.

4. Stability after reconstitution. The sponsor must establish the usable period after addition of sodium pertechnetate Tc 99m.

5. Container-closure compatibility. The stopper, vial, and any transfer device must not reduce kit performance or introduce extractables and leachables concerns.

6. Labeling. Instructions must cover reconstitution, storage, expiration after radiolabeling, radiochemical testing, and dose preparation.

FDA's approved labeling identifies Myoview as a diagnostic drug product rather than a therapeutic biologic. Biosimilar approval concepts therefore do not apply. Competitive risk comes from generic or alternative radiopharmaceutical products, not biosimilar substitution.[1,4]

What patents and exclusivity protect Myoview?

Myoview's original composition and regulatory exclusivity periods are historical rather than current commercial barriers. The product was approved in the 1990s, so any original FDA exclusivity has expired. The commercial protection of a new Myoview-type product would more likely come from manufacturing know-how, formulation patents, device integration, trademarks, supply contracts, and regulatory execution.

Potential patentable subject matter includes:

• Specific tetrofosmin-to-stannous ratios.
• Lyophilized compositions with defined residual-moisture ranges.
• Stabilized radiolabeling kits.
• Container-closure systems that limit oxidation.
• Automated reconstitution devices.
• Methods that improve labeling efficiency or reduce free technetium.
• Shelf-stable formulations under defined temperature conditions.
• Manufacturing processes for high-purity tetrofosmin.

A formulation patent would need meaningful technical boundaries. Broad claims covering tetrofosmin, technetium, or generic radiolabeling concepts are more vulnerable to validity and enablement challenges because the technology is established.

The relevant freedom-to-operate review should cover United States, European Union, Japan, China, and major nuclear-medicine markets. It should include expired platform patents, active formulation claims, process patents, device patents, and third-party rights relating to tetrofosmin manufacture.

How strong is the patent estate for a new Myoview excipient product?

The patent estate would be moderate if it relies only on known excipients and standard lyophilization. It could be stronger if the sponsor can show an unexpected technical effect, such as:

• A measurable increase in shelf life.
• Consistently higher radiochemical purity.
• Lower free-technetium formation under stressed conditions.
• Improved performance across multiple generator eluate concentrations.
• Reduced reconstitution failures.
• Better compatibility with automated compounding.

The strongest claims would combine composition and performance limits. For example, a claim directed to a defined ligand/reducing-agent ratio, moisture range, and radiochemical-purity threshold may provide more defensible protection than a claim covering a broad list of optional excipients.

Which companies and products challenge Myoview commercially?

The competitive set includes GE HealthCare's Myoview, Lantheus's Cardiolite franchise and generic sestamibi products, and other suppliers of technetium-based myocardial perfusion kits. Competition is shaped by hospital contracts, nuclear pharmacy relationships, isotope availability, manufacturing reliability, and reimbursement rather than by consumer brand recognition.

The principal competitive threats are:

• Lower-priced generic sestamibi.
• Contract suppliers offering reliable kit availability.
• Products with longer dating.
• Products optimized for automated compounding.
• Regional manufacturers with lower distribution costs.
• Alternative cardiac imaging modalities, including PET myocardial perfusion imaging and stress echocardiography.

A new tetrofosmin kit would have the clearest commercial opening where it can reduce operational cost or address supply shortages without requiring hospitals to change established imaging protocols.

What generic launch risks exist?

A generic launch could occur through a product-specific FDA pathway, but commercial entry would face several barriers:

• Complex radiopharmaceutical manufacturing.
• Short radioactive operating windows after labeling.
• Need for specialized quality-control testing.
• Limited manufacturing sites capable of sterile kit production.
• Hospital validation requirements.
• Nuclear-pharmacy training and workflow adaptation.
• Small market size relative to conventional injectable generics.
• Exposure to isotope supply disruptions.

Paragraph IV litigation is less likely to be the primary barrier for an old radiopharmaceutical product than it is for a recently approved small-molecule drug with active Orange Book patents. Any applicant still must evaluate active formulation, process, device, and method-of-use patents before launch. The absence of a major active patent barrier does not eliminate regulatory or manufacturing risk.

What licensing and partnership models are commercially viable?

The most practical models are operational partnerships rather than pure patent licenses.

Partnership model	Commercial rationale
Regional manufacturing license	Reduces transport time and improves local supply
Contract manufacturing	Avoids construction of a dedicated sterile lyophilization facility
Nuclear-pharmacy distribution agreement	Provides access to radiolabeling sites and hospital accounts
Automated-compounding partnership	Embeds the kit in validated pharmacy workflows
Co-development with an imaging supplier	Combines formulation expertise with clinical distribution
Supply agreement with a generator manufacturer	Links kit availability to technetium supply and customer retention

A formulation owner should seek claims and know-how that remain valuable after patent expiry. These may include validated lyophilization cycles, raw-material specifications, automated-compounding settings, analytical methods, and stability datasets.

Key Takeaways

• Myoview is a technetium Tc 99m tetrofosmin lyophilized kit for myocardial perfusion imaging.
• Its excipient system supports technetium reduction, ligand complexation, stability, sterility, and reconstitution.
• The highest-value formulation opportunities are longer dating, improved moisture and oxygen resistance, faster reconstitution, and automated-compounding compatibility.
• Biosimilar competition is not relevant because Myoview is a diagnostic radiopharmaceutical, not a biologic.
• Original regulatory exclusivity is historical; new commercial protection would depend on formulation, process, device, and manufacturing IP.
• A generic or follow-on product would face substantial CMC, sterility, radiochemical testing, isotope supply, and hospital-validation requirements.
• The strongest commercial strategy combines a technically robust kit with nuclear-pharmacy distribution and automated workflow integration.

FAQs

Can Myoview excipients be replaced without new clinical studies?

Possibly, but the sponsor would need to establish that the change does not alter radiochemical purity, stability, biodistribution, sterility, or clinical performance. The regulatory burden depends on the scale and nature of the change.

Does Myoview contain radioactive technetium when shipped?

No. The kit is shipped without Tc 99m. Sodium pertechnetate Tc 99m is added by an authorized radiopharmacy or hospital nuclear-medicine facility before use.

Is tetrofosmin protected by an active Orange Book patent?

Myoview is an old product, and its original exclusivity period has expired. Current freedom-to-operate requires a claim-by-claim review of active formulation, process, device, and method patents rather than reliance on original product approval dates.

What excipient would most improve Myoview shelf life?

No single excipient is likely to determine shelf life. Moisture control, oxygen exposure, vial closure, lyophilization cycle, and the stability of the stannous reducing system are interdependent.

Could a new Myoview formulation receive a 505(b)(2) approval?

A 505(b)(2) strategy may be considered where the applicant relies partly on an existing approved product while introducing a meaningful formulation or manufacturing change. Product-specific FDA requirements would determine whether the pathway is available.

References

1. U.S. Food and Drug Administration. (n.d.). Myoview (kit for the preparation of technetium Tc 99m tetrofosmin injection) prescribing information.
2. DailyMed. (n.d.). MYOVIEW- kit for the preparation of technetium tc 99m tetrofosmin injection. National Library of Medicine.
3. American Society of Nuclear Cardiology. (2010). ASNC imaging guidelines for nuclear cardiology procedures: Myocardial perfusion imaging. Journal of Nuclear Cardiology.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.